- Home
- Publications
- Publication Search
- Publication Details
Title
Drug development progress in duchenne muscular dystrophy
Authors
Keywords
-
Journal
Frontiers in Pharmacology
Volume 13, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2022-07-22
DOI
10.3389/fphar.2022.950651
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Repeated intravenous cardiosphere-derived cell therapy in late-stage Duchenne muscular dystrophy (HOPE-2): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
- (2022) Craig M McDonald et al. LANCET
- Long-Term Functional Efficacy and Safety of Viltolarsen in Patients with Duchenne Muscular Dystrophy
- (2022) Paula R. Clemens et al. Journal of Neuromuscular Diseases
- Food and Drug Administration Lifts Clinical Hold on Pfizer Duchenne Muscular Dystrophy Gene Therapy Linked to Patient Death
- (2022) Alex Philippidis HUMAN GENE THERAPY
- Corrigendum to “Randomized phase 2 trial and open-label extension of domagrozumab in Duchenne muscular dystrophy” [Neuromuscular Disorders, Vol. 30 (6) 2020, 492-502]
- (2021) Kathryn R. Wagner et al. NEUROMUSCULAR DISORDERS
- Genotype characterization and delayed loss of ambulation by glucocorticoids in a large cohort of patients with Duchenne muscular dystrophy
- (2021) Shu Zhang et al. Orphanet Journal of Rare Diseases
- Safety, tolerability, and pharmacokinetics of casimersen in patients with D uchenne muscular dystrophy amenable to exon 45 skipping: A randomized, double‐blind, placebo‐controlled, dose‐titration trial
- (2021) Kathryn R. Wagner et al. MUSCLE & NERVE
- Open-Label Evaluation of Eteplirsen in Patients with Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping: PROMOVI Trial
- (2021) Craig M. McDonald et al. Journal of Neuromuscular Diseases
- Pharmacology and toxicology of eteplirsen and SRP-5051 for DMD exon 51 skipping: an update
- (2021) Omar Sheikh et al. ARCHIVES OF TOXICOLOGY
- Gene therapy community grapples with toxicity issues, as pipeline matures
- (2021) Asher Mullard NATURE REVIEWS DRUG DISCOVERY
- Long-Term Safety and Efficacy Data of Golodirsen in Ambulatory Patients with Duchenne Muscular Dystrophy Amenable to Exon 53 Skipping: A First-in-human, Multicenter, Two-Part, Open-Label, Phase 1/2 Trial
- (2021) Laurent Servais et al. Nucleic Acid Therapeutics
- Editorial: “AAV Gene Therapy: Immunology and Immunotherapeutics”
- (2021) José M. Martinez-Navio et al. Frontiers in Immunology
- Development of a model‐based clinical trial simulation platform to optimize the design of clinical trials for Duchenne muscular dystrophy
- (2021) Karthik Lingineni et al. CPT-Pharmacometrics & Systems Pharmacology
- Increased dystrophin production with golodirsen in patients with Duchenne muscular dystrophy
- (2020) Diane E. Frank et al. NEUROLOGY
- Randomized phase 2 trial and open-label extension of domagrozumab in Duchenne muscular dystrophy
- (2020) Kathryn R. Wagner et al. NEUROMUSCULAR DISORDERS
- Safety, Tolerability, and Efficacy of Viltolarsen in Boys With Duchenne Muscular Dystrophy Amenable to Exon 53 Skipping
- (2020) Paula R. Clemens et al. JAMA Neurology
- Longitudinal Study of Three microRNAs in Duchenne Muscular Dystrophy and Becker Muscular Dystrophy
- (2020) Selena Trifunov et al. Frontiers in Neurology
- Suitability of external controls for drug evaluation in Duchenne muscular dystrophy
- (2020) Nathalie Goemans et al. NEUROLOGY
- Assessment of Systemic Delivery of rAAVrh74.MHCK7.micro-dystrophin in Children With Duchenne Muscular Dystrophy
- (2020) Jerry R. Mendell et al. JAMA Neurology
- Efficacy and safety of vamorolone in Duchenne muscular dystrophy: An 18-month interim analysis of a non-randomized open-label extension study
- (2020) Edward C. Smith et al. PLOS MEDICINE
- Viltolarsen in Japanese Duchenne muscular dystrophy patients: A phase 1/2 study
- (2020) Hirofumi Komaki et al. Annals of Clinical and Translational Neurology
- Cardiac and skeletal muscle effects in the randomized HOPE-Duchenne trial
- (2019) Michael Taylor et al. NEUROLOGY
- Effect and safety of treatment with ACE-inhibitor Enalapril and β-blocker metoprolol on the onset of left ventricular dysfunction in Duchenne muscular dystrophy - a randomized, double-blind, placebo-controlled trial
- (2019) Sven Dittrich et al. Orphanet Journal of Rare Diseases
- 238th ENMC International Workshop: Updating management recommendations of cardiac dystrophinopathy - 30 November–2 December 2018
- (2019) John P. Bourke et al. NEUROMUSCULAR DISORDERS
- Vamorolone trial in Duchenne muscular dystrophy shows dose-related improvement of muscle function
- (2019) Eric P. Hoffman et al. NEUROLOGY
- Pamrevlumab, an anti-connective tissue growth factor therapy, for idiopathic pulmonary fibrosis (PRAISE): a phase 2, randomised, double-blind, placebo-controlled trial
- (2019) Luca Richeldi et al. Lancet Respiratory Medicine
- Stabilization of Early Duchenne Cardiomyopathy With Aldosterone Inhibition: Results of the Multicenter AIDMD Trial
- (2019) Subha V. Raman et al. Journal of the American Heart Association
- Muscular Dystrophies
- (2018) John C. Carter et al. CLINICS IN CHEST MEDICINE
- Long-term effects of glucocorticoids on function, quality of life, and survival in patients with Duchenne muscular dystrophy: a prospective cohort study
- (2018) Craig M McDonald et al. LANCET
- Diagnosis and management of Duchenne muscular dystrophy, part 3: primary care, emergency management, psychosocial care, and transitions of care across the lifespan
- (2018) David J Birnkrant et al. LANCET NEUROLOGY
- Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management
- (2018) David J Birnkrant et al. LANCET NEUROLOGY
- Diagnosis and management of Duchenne muscular dystrophy, part 2: respiratory, cardiac, bone health, and orthopaedic management
- (2018) David J Birnkrant et al. LANCET NEUROLOGY
- Systemic AAV micro-dystrophin gene therapy for Duchenne muscular dystrophy
- (2018) Dongsheng Duan MOLECULAR THERAPY
- Eteplirsen treatment for Duchenne muscular dystrophy
- (2018) Jay S. Charleston et al. NEUROLOGY
- Muscle miRNAome shows suppression of chronic inflammatory miRNAs with both prednisone and vamorolone
- (2018) Alyson A Fiorillo et al. PHYSIOLOGICAL GENOMICS
- Systemic administration of the antisense oligonucleotide NS-065/NCNP-01 for skipping of exon 53 in patients with Duchenne muscular dystrophy
- (2018) Hirofumi Komaki et al. Science Translational Medicine
- Phase 1 trial of vamorolone, a first-in-class steroid, shows improvements in side effects via biomarkers bridged to clinical outcomes
- (2018) Eric P. Hoffman et al. STEROIDS
- Therapeutic Mechanisms of Glucocorticoids
- (2018) Jolien Vandewalle et al. TRENDS IN ENDOCRINOLOGY AND METABOLISM
- Phase IIa trial in Duchenne muscular dystrophy shows vamorolone is a first-in-class dissociative steroidal anti-inflammatory drug
- (2018) Laurie S. Conklin et al. PHARMACOLOGICAL RESEARCH
- Cardiac Management of the Patient With Duchenne Muscular Dystrophy
- (2018) Sujatha Buddhe et al. PEDIATRICS
- Ataluren in patients with nonsense mutation Duchenne muscular dystrophy (ACT DMD): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
- (2017) Craig M McDonald et al. LANCET
- A phase 3 randomized placebo-controlled trial of tadalafil for Duchenne muscular dystrophy
- (2017) Ronald G. Victor et al. NEUROLOGY
- Long-term microdystrophin gene therapy is effective in a canine model of Duchenne muscular dystrophy
- (2017) Caroline Le Guiner et al. Nature Communications
- FDA Approves Eteplirsen for Duchenne Muscular Dystrophy: The Next Chapter in the Eteplirsen Saga
- (2017) Annemieke Aartsma-Rus et al. Nucleic Acid Therapeutics
- Development of Exon Skipping Therapies for Duchenne Muscular Dystrophy: A Critical Review and a Perspective on the Outstanding Issues
- (2017) Annemieke Aartsma-Rus et al. Nucleic Acid Therapeutics
- mTOR as a Key Regulator in Maintaining Skeletal Muscle Mass
- (2017) Mee-Sup Yoon Frontiers in Physiology
- Cardiomyopathy in Muscular Dystrophy
- (2017) Elizabeth M. McNally JAMA Cardiology
- The importance of genetic diagnosis for Duchenne muscular dystrophy
- (2016) Annemieke Aartsma-Rus et al. JOURNAL OF MEDICAL GENETICS
- Synthesis and Characterization of Fatty Acid Conjugates of Niacin and Salicylic Acid
- (2016) Chi B. Vu et al. JOURNAL OF MEDICINAL CHEMISTRY
- BMS-986089: A novel adnectin protein that dose dependently lowers free myostatin and increases muscle volume and lean body mass
- (2016) L. Jacobsen et al. NEUROMUSCULAR DISORDERS
- Categorizing natural history trajectories of ambulatory function measured by the 6-minute walk distance in patients with Duchenne muscular dystrophy
- (2016) Eugenio Mercuri et al. NEUROMUSCULAR DISORDERS
- Histological effects of givinostat in boys with Duchenne muscular dystrophy
- (2016) Paolo Bettica et al. NEUROMUSCULAR DISORDERS
- Absence of Dystrophin Disrupts Skeletal Muscle Signaling: Roles of Ca2+, Reactive Oxygen Species, and Nitric Oxide in the Development of Muscular Dystrophy
- (2016) David G. Allen et al. PHYSIOLOGICAL REVIEWS
- Anti-inflammatory drugs for Duchenne muscular dystrophy: focus on skeletal muscle-releasing factors
- (2016) Yoshitsugu Aoki et al. Drug Design Development and Therapy
- Tadalafil Treatment Delays the Onset of Cardiomyopathy in Dystrophin‐Deficient Hearts
- (2016) David W. Hammers et al. Journal of the American Heart Association
- Twenty-Four Hour Noninvasive Ventilation in Duchenne Muscular Dystrophy: A Safe Alternative to Tracheostomy
- (2016) Douglas A McKim et al. Canadian Respiratory Journal
- Safety, Tolerability, and Pharmacokinetics of SMT C1100, a 2-Arylbenzoxazole Utrophin Modulator, following Single- and Multiple-Dose Administration to Pediatric Patients with Duchenne Muscular Dystrophy
- (2016) Valeria Ricotti et al. PLoS One
- Individualized Prediction of Changes in 6-Minute Walk Distance for Patients with Duchenne Muscular Dystrophy
- (2016) Nathalie Goemans et al. PLoS One
- How much dystrophin is enough: the physiological consequences of different levels of dystrophin in themdxmouse
- (2015) Caroline Godfrey et al. HUMAN MOLECULAR GENETICS
- The TREAT-NMD DMD Global Database: Analysis of More than 7,000 Duchenne Muscular Dystrophy Mutations
- (2015) Catherine L. Bladen et al. HUMAN MUTATION
- Efficacy of idebenone on respiratory function in patients with Duchenne muscular dystrophy not using glucocorticoids (DELOS): a double-blind randomised placebo-controlled phase 3 trial
- (2015) Gunnar M Buyse et al. LANCET
- Eplerenone for early cardiomyopathy in Duchenne muscular dystrophy: a randomised, double-blind, placebo-controlled trial
- (2015) Subha V Raman et al. LANCET NEUROLOGY
- The first exon duplication mouse model of Duchenne muscular dystrophy: A tool for therapeutic development
- (2015) Adeline Vulin et al. NEUROMUSCULAR DISORDERS
- European Medicines Agency review of ataluren for the treatment of ambulant patients aged 5 years and older with Duchenne muscular dystrophy resulting from a nonsense mutation in the dystrophin gene
- (2015) Manuel Haas et al. NEUROMUSCULAR DISORDERS
- Nutrition Considerations in Duchenne Muscular Dystrophy
- (2015) Jillian Davis et al. NUTRITION IN CLINICAL PRACTICE
- Sildenafil does not improve cardiomyopathy in Duchenne/Becker muscular dystrophy
- (2014) Doris G. Leung et al. ANNALS OF NEUROLOGY
- Idebenone and neuroprotection: antioxidant, pro-oxidant, or electron carrier?
- (2014) Sausan Jaber et al. JOURNAL OF BIOENERGETICS AND BIOMEMBRANES
- Ataluren treatment of patients with nonsense mutation dystrophinopathy
- (2014) Katharine Bushby et al. MUSCLE & NERVE
- PDE5 inhibition alleviates functional muscle ischemia in boys with Duchenne muscular dystrophy
- (2014) M. D. Nelson et al. NEUROLOGY
- Omega-3 Free Fatty Acids Suppress Macrophage Inflammasome Activation by Inhibiting NF-κB Activation and Enhancing Autophagy
- (2014) Yolanda Williams-Bey et al. PLoS One
- Eteplirsen for the treatment of Duchenne muscular dystrophy
- (2013) Jerry R. Mendell et al. ANNALS OF NEUROLOGY
- Myostatin acts as an autocrine/paracrine negative regulator in myoblast differentiation from human induced pluripotent stem cells
- (2013) Fei Gao et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Newborn bloodspot screening for Duchenne Muscular Dystrophy: 21 years experience in Wales (UK)
- (2013) Stuart J Moat et al. EUROPEAN JOURNAL OF HUMAN GENETICS
- All-Cause Mortality and Cardiovascular Outcomes With Prophylactic Steroid Therapy in Duchenne Muscular Dystrophy
- (2013) Gernot Schram et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Unknown
- (2013) Silvia Consalvi et al. MOLECULAR MEDICINE
- Microdystrophin Ameliorates Muscular Dystrophy in the Canine Model of Duchenne Muscular Dystrophy
- (2013) Jin-Hong Shin et al. MOLECULAR THERAPY
- Phase 2a Study of Ataluren-Mediated Dystrophin Production in Patients with Nonsense Mutation Duchenne Muscular Dystrophy
- (2013) Richard S. Finkel et al. PLoS One
- Evidence-based path to newborn screening for duchenne muscular dystrophy
- (2012) Jerry R. Mendell et al. ANNALS OF NEUROLOGY
- Sildenafil reduces respiratory muscle weakness and fibrosis in the mdx mouse model of Duchenne muscular dystrophy
- (2012) Justin M Percival et al. JOURNAL OF PATHOLOGY
- Muscle Function Recovery in Golden Retriever Muscular Dystrophy After AAV1-U7 Exon Skipping
- (2012) Adeline Vulin et al. MOLECULAR THERAPY
- Effects of glucocorticoids and idebenone on respiratory function in patients with duchenne muscular dystrophy
- (2012) Gunnar M. Buyse et al. PEDIATRIC PULMONOLOGY
- The Effects of Low Levels of Dystrophin on Mouse Muscle Function and Pathology
- (2012) Maaike van Putten et al. PLoS One
- Dystrophin quantification and clinical correlations in Becker muscular dystrophy: implications for clinical trials
- (2011) K. Anthony et al. BRAIN
- Early Treatment With Lisinopril and Spironolactone Preserves Cardiac and Skeletal Muscle in Duchenne Muscular Dystrophy Mice
- (2011) Jill A. Rafael-Fortney et al. CIRCULATION
- Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study
- (2011) Sebahattin Cirak et al. LANCET
- Endpoint measures in the mdx mouse relevant for muscular dystrophy pre-clinical studies
- (2011) Yvonne M. Kobayashi et al. NEUROMUSCULAR DISORDERS
- Antibody-Directed Myostatin Inhibition Improves Diaphragm Pathology in Young but not Adult Dystrophic mdx Mice
- (2010) Kate T. Murphy et al. AMERICAN JOURNAL OF PATHOLOGY
- Duchenne Muscular Dystrophy
- (2010) John R. Bach et al. AMERICAN JOURNAL OF PHYSICAL MEDICINE & REHABILITATION
- Sildenafil reverses cardiac dysfunction in the mdx mouse model of Duchenne muscular dystrophy
- (2010) C. M. Adamo et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Theoretic applicability of antisense-mediated exon skipping for Duchenne muscular dystrophy mutations
- (2009) Annemieke Aartsma-Rus et al. HUMAN MUTATION
- Capacity of Omega-3 Fatty Acids or Eicosapentaenoic Acid to Counteract Weightlessness-Induced Bone Loss by Inhibiting NF-κB Activation: From Cells to Bed Rest to Astronauts
- (2009) Sara R Zwart et al. JOURNAL OF BONE AND MINERAL RESEARCH
- Mechanisms of mineralocorticoid receptor-mediated cardiac fibrosis and vascular inflammation
- (2008) Morag J Young CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION
- Sarcolemma-localized nNOS is required to maintain activity after mild exercise
- (2008) Yvonne M. Kobayashi et al. NATURE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now